Want to see BTMD full AI Analyst Report?
BTMD Stock Chart & Stats
$1.55
$0.06(2.63%)
At close: 4:00 PM EDT
$1.55
$0.06(2.63%)
Day’s Range― - ―
52-Week Range$1.00 - $2.98
Previous CloseN/A
Volume52.46K
Average Volume (3M)127.47K
Market Cap
$42.39M
Enterprise Value$179.17M
Total Cash (Recent Filing)$11.17M
Total Debt (Recent Filing)$128.64M
Price to Earnings (P/E)7.0
Beta1.37
Next Earnings
Nov 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding28,677,590
10 Day Avg. Volume113,543
30 Day Avg. Volume127,468
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.39
Price to Sales (P/S)0.42
P/FCF Ratio2.70
Enterprise Value/Market Cap4.23
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit1.62
Enterprise Value/Ebitda7.64
Forecast
1Y Price Target
$2.00Price Target Upside29.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.03
Revenue Forecast (FY)$178.00M
Bulls Say, Bears Say
Bulls Say
Provider-network Recurring Revenue ModelBiote’s clinic-support model can build recurring reorder activity because enrolled providers purchase therapy products for ongoing patient procedures. Continued provider expansion and retention may therefore support repeat revenue and deepen the platform’s commercial reach over the next several quarters.
Positive Cash Generation And Business TurnaroundPositive operating and free cash flow show that Biote has demonstrated an ability to convert operations into cash, while the multi-year move from losses to profitability indicates meaningful business improvement. This provides a foundation for funding operations internally despite recent softness.
Supplement Growth And Healthy Gross MarginSupplement growth provides a complementary revenue stream beyond hormone procedures and is expected to expand at a mid- to high-single-digit rate in 2026. Combined with a still-strong gross margin, this mix can support profitability and diversify the provider offering.
Bears Say
Negative Equity And Sizable DebtPersistent negative equity and debt exceeding the asset base materially reduce financial flexibility. This structure can constrain investment, make the company more vulnerable to earnings volatility, and increase the consequences of any sustained operating downturn over the next several quarters.
Revenue And Earnings DeteriorationThe decline in revenue, swing to a GAAP loss, and reduced annual targets indicate that recent operating weakness is affecting both scale and earnings power. If recovery is slower than expected, lower profitability could weaken cash generation and delay balance-sheet improvement.
Clinic Attrition And Weaker Procedure ProductivityHigh clinic attrition directly threatens the provider base that drives procedure volumes and recurring product orders. Slower productivity among new clinics further delays network expansion, making a return to procedure growth less certain and limiting operating leverage across the platform.
biote News
BTMD FAQ
What was biote’s price range in the past 12 months?
biote lowest stock price was $1.00 and its highest was $2.98 in the past 12 months.
What is biote’s market cap?
biote’s market cap is $42.39M.
When is biote’s upcoming earnings report date?
biote’s upcoming earnings report date is Nov 04, 2026 which is in 7 days.
How were biote’s earnings last quarter?
biote released its earnings results on Aug 05, 2026. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of $0.027 by -$0.257.
Is biote overvalued?
According to Wall Street analysts biote’s price is currently Undervalued.
Does biote pay dividends?
biote does not currently pay dividends.
What is biote’s EPS estimate?
biote’s EPS estimate is >-0.01.
How many shares outstanding does biote have?
biote has 28,677,590 shares outstanding.
What happened to biote’s price movement after its last earnings report?
biote reported an EPS of -$0.23 in its last earnings report, missing expectations of $0.027. Following the earnings report the stock price went down -27.876%.
Which hedge fund is a major shareholder of biote?
Currently, no hedge funds are holding shares in BTMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.00 (29.03% Upside)
$2.00 (29.03% Upside)
Insider Transactions
Bought Shares
Worth $202.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.31%
12-Months-Change
Fundamentals
Return on Equity
-9.25%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
biote
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
BTMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call contained meaningful operational progress — restored supply, normalized inventory, a stronger commercial team, positive adjusted EBITDA, and growing supplements revenue — but these positives were outweighed by significant near-term financial headwinds: total revenue fell 9.5%, procedure revenue declined 13.9% (with a $3.3M recall impact), gross margin compressed by 6.2 percentage points, SG&A rose materially (driven by legal costs), the company swung to a GAAP net loss of $7.4M, and management cut full-year guidance (revenue and adjusted EBITDA). While management expects sequential improvement in H2 2026, the magnitude of the year-over-year deterioration and the guidance reductions dominate the call's tone.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$2.00
▲(29.03% Upside)
Technical Analysis
Concord Medical Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
9.99% Insiders
9.82% Mutual Funds
0.13% Other Institutional Investors
74.68% Public Companies and
Individual Investors